Tags

Type your tag names separated by a space and hit enter

[Drug treatment of obesity].
Ugeskr Laeger. 2006 Jan 09; 168(2):163-7.UL

Abstract

Acceptable adverse effects and a clinical relevant weight loss of 3 to 5 kilograms have been found in long-term randomized clinical trials for sibutramine (Reductil) and orlistat (Xenical); these drugs may be prescribed for treatment of obesity for a duration of one and four years, respectively. This also seems to be the case for rimonabant (Acomplia), which is expected to receive approval in 2005 or 2006. However, until data on morbidity and mortality are available from RCTs, there is no absolute indication for prescribing drugs for treatment of obesity.

Authors+Show Affiliations

Astrup H:S Bispebjerg Hospital, Endokrinologisk Sektion, Intern Medicinsk Klinik I, København NV. ols01@bbh.hosp.dkNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

dan

PubMed ID

16403342

Citation

Svendsen, Ole Lander, et al. "[Drug Treatment of Obesity]." Ugeskrift for Laeger, vol. 168, no. 2, 2006, pp. 163-7.
Svendsen OL, Toubro S, Breum L, et al. [Drug treatment of obesity]. Ugeskr Laeg. 2006;168(2):163-7.
Svendsen, O. L., Toubro, S., Breum, L., Bruun, J. M., & Astrup, A. V. (2006). [Drug treatment of obesity]. Ugeskrift for Laeger, 168(2), 163-7.
Svendsen OL, et al. [Drug Treatment of Obesity]. Ugeskr Laeg. 2006 Jan 9;168(2):163-7. PubMed PMID: 16403342.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Drug treatment of obesity]. AU - Svendsen,Ole Lander, AU - Toubro,Søren, AU - Breum,Leif, AU - Bruun,Jens Meldgaard, AU - Astrup,Arne V, PY - 2006/1/13/pubmed PY - 2006/1/25/medline PY - 2006/1/13/entrez SP - 163 EP - 7 JF - Ugeskrift for laeger JO - Ugeskr. Laeg. VL - 168 IS - 2 N2 - Acceptable adverse effects and a clinical relevant weight loss of 3 to 5 kilograms have been found in long-term randomized clinical trials for sibutramine (Reductil) and orlistat (Xenical); these drugs may be prescribed for treatment of obesity for a duration of one and four years, respectively. This also seems to be the case for rimonabant (Acomplia), which is expected to receive approval in 2005 or 2006. However, until data on morbidity and mortality are available from RCTs, there is no absolute indication for prescribing drugs for treatment of obesity. SN - 1603-6824 UR - https://www.unboundmedicine.com/medline/citation/16403342/[Drug_treatment_of_obesity]_ L2 - http://www.diseaseinfosearch.org/result/9028 DB - PRIME DP - Unbound Medicine ER -